What is Blueprint Medicines Financial Strength?
Blueprint Medicines has the Financial Strength Rank of 5.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Blueprint Medicines did not have earnings to cover the interest expense.
Blueprint Medicines's debt to revenue ratio for the quarter that ended in Dec. 2024 was 0.80.
As of today, Blueprint Medicines's Altman Z-Score is 2.28.
Competitive Comparison of Blueprint Medicines's Financial Strength
For the Biotechnology subindustry, Blueprint Medicines's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blueprint Medicines's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Financial Strength distribution charts can be found below:
* The bar in red indicates where Blueprint Medicines's Financial Strength falls into.
Blueprint Medicines Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Blueprint Medicines's Interest Expense for the
months ended in Dec. 2024 was $-18.2 Mil. Its Operating Income for the
months ended in Dec. 2024 was $-41.2 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $411.8 Mil.
Blueprint Medicines's Interest Coverage for the quarter that ended in Dec. 2024 is
| Blueprint Medicines did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Blueprint Medicines's Debt to Revenue Ratio for the quarter that ended in Dec. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Blueprint Medicines has a Z-score of 2.28, indicating it is in Grey Zones. This implies that Blueprint Medicines is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.
Warning Sign:
Altman Z-score of 2.28 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blueprint Medicines Business Description
Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
Executives
| Christina Rossi |
officer: Chief Commercial Officer |
45 SIDNEY STREET, BLUEPRINT MEDICINES CORPORATION, CAMBRIDGE MA 02139 |
| Jeffrey W. Albers |
director, officer: CEO & President |
BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142 |
| Kate Haviland |
officer: Chief Business Officer |
BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139 |
| Ariel Hurley |
officer: Principal Accounting Officer |
C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139 |
| Lonnel Coats |
director |
8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
| Fouad Namouni |
officer: President, R and D |
535 BOYLSTON ST., 2ND FLOOR, BOSTON MA 02116 |
| Michael Landsittel |
officer: Principal FAO |
BLUEPRINT MEDICINES CORP., 214 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142 |
| Philina Lee |
officer: Chief Commercial Officer |
C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6 |
| Debra Durso-bumpus |
officer: Chief People Officer |
C/O BLUEPRINT MEDICINES CORORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139 |
| Percy H. Carter |
officer: Chief Scientific Officer |
C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139 |
| L. Becker Hewes |
officer: Chief Medical Officer |
C/O BLUEPRINT MEDICINES, CORPORATION, CAMBRIDGE MA 02139 |
| Christopher K. Murray |
officer: SVP, Technical Operations |
C/O BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139 |
| Tracey L Mccain |
officer: EVP and Chief Legal Officer |
C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139 |
| John Tsai |
director |
BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139 |
| Habib J Dable |
director |
C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139 |
Blueprint Medicines Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BPMC has been successfully added to your